Posted inCardiagtech

Acute Cystitis Differential Diagnosis: A Comprehensive Guide

No Comments

Introduction

Cystitis, commonly known as a bladder infection, is an inflammation of the urinary bladder, frequently caused by a bacterial infection. It’s broadly classified into uncomplicated and complicated cystitis. Uncomplicated cystitis typically occurs in healthy individuals, particularly non-pregnant women, while complicated cystitis is associated with underlying conditions that can increase treatment failure or infection severity. Acute cystitis, the focus of this article, is usually bacterial in origin and is significantly more prevalent in women due to anatomical factors. Recognizing the various conditions that can mimic acute cystitis is crucial for accurate diagnosis and effective management. This article delves into the differential diagnosis of acute cystitis, providing a comprehensive overview for healthcare understanding and SEO optimization.

Etiology of Acute Cystitis

Bacterial infection is the primary cause of acute cystitis. Escherichia coli (E. coli) is the most frequently identified pathogen, accounting for 75% to 95% of uncomplicated cases in women. Other bacteria, including Klebsiella, Proteus mirabilis, Staphylococcus saprophyticus, and Enterococcus species, can also be causative agents. In complicated cystitis, the range of potential pathogens expands to include Enterobacter, Citrobacter, Serratia, Pseudomonas, and even fungi, often exhibiting higher rates of antimicrobial resistance.

Epidemiology of Cystitis

Urinary tract infections (UTIs) are remarkably common, particularly among women. It’s estimated that approximately one-third of women will experience a UTI by the age of 24, and half by age 32. Annually, around 12% of women report experiencing a UTI. Risk factors for uncomplicated cystitis in women include sexual activity, spermicide use, a new sexual partner, a history of UTIs, family history of UTIs in female relatives, and being post-menopausal. Acute cystitis is considerably more common than pyelonephritis, with estimates suggesting 18 to 28 cases of cystitis for every pyelonephritis case.

Complicated UTIs have varying incidence rates depending on the underlying health conditions. For example, women with diabetes have a higher prevalence of asymptomatic bacteriuria (26%) compared to non-diabetic women (6%). Conditions such as renal transplantation, pregnancy, nephrolithiasis, immunocompromised states, urinary catheters, urinary tract abnormalities, and renal insufficiency also increase the risk of complicated UTIs. Simple cystitis is less common in men, with fewer than 10 cases per 10,000 men under 65 years old annually.

Pathophysiology of Acute Cystitis

The development of cystitis typically begins with bacteria colonizing the periurethral area, often originating from fecal or vaginal flora. These bacteria then ascend to the urinary bladder. Uropathogens possess virulence factors that enable them to evade host defenses and infect urinary tract tissues. UTIs are less frequent in males due to the longer urethra, drier periurethral environment, and antibacterial properties of prostatic fluid. While traditionally, all UTIs in men were considered complicated, uncomplicated UTIs can occur in men aged 15 to 50, especially those sexually active, uncircumcised, or practicing anal intercourse, provided they lack risk factors for complicated UTIs.

Complicated UTIs are often influenced by host factors. Conditions like diabetes, renal insufficiency, kidney stones, and urinary catheterization can significantly alter the pathogenesis of UTIs, making individuals more susceptible due to impaired immunity, voiding dysfunction, reduced antimicrobial clearance, obstruction, or biofilm formation on catheters.

History and Physical Examination in Acute Cystitis

Patients with acute cystitis commonly present with urinary symptoms such as dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and sometimes hematuria (blood in urine). In women, dysuria and urinary frequency without vaginal discharge or irritation are strong indicators of uncomplicated cystitis. However, symptoms can be atypical, especially in very young or elderly individuals.

[alt text: Illustration depicting the female urinary system, highlighting the bladder and urethra, common sites of cystitis infections.]

Differentiating cystitis from pyelonephritis is important. Pyelonephritis, an upper UTI, typically involves systemic symptoms like fever, chills, flank pain, costovertebral angle tenderness, nausea, and vomiting, which are usually absent in uncomplicated cystitis.

A thorough patient history should include previous UTIs, recent antibiotic use, and risk factors for complicated infections such as diabetes, immunocompromised status, recent urologic procedures, kidney stones, or pregnancy. A pelvic exam is often recommended for women, especially those with recurrent UTIs, to rule out other conditions.

Evaluation and Diagnosis of Acute Cystitis

Diagnosis of acute cystitis is often clinical, based on symptoms suggestive of lower UTI and laboratory confirmation of pyuria (white blood cells in urine) and/or nitrites in the urine. While physical exams may be less crucial for cystitis, they are important for suspected pyelonephritis or vaginitis. In young, non-pregnant women with typical symptoms and no vaginal discharge, diagnosis and treatment can sometimes be initiated based on clinical suspicion alone. However, urinalysis and urine culture are generally recommended before starting antibiotics, especially if initial treatment fails.

Urinalysis is a key diagnostic tool. A clean-catch urine sample is usually sufficient. Pyuria, defined as ≥10 WBCs/HPF, is almost always present in cystitis, and its absence suggests alternative diagnoses. Urine dipsticks can detect leukocyte esterase (produced by leukocytes) and nitrites (indicating Enterobacteriaceae). Positive dipstick tests support a cystitis diagnosis, but negative results do not rule it out. Urine culture is useful for identifying pathogens and their antibiotic sensitivities, especially in complicated or recurrent cases, and for guiding treatment if initial therapy fails. Urine cultures are essential for men with cystitis and women with risk factors for complicated UTIs.

Radiographic imaging, such as CT scans or ultrasounds, may be necessary for patients with complicated cystitis who do not respond to treatment within 48 to 72 hours, to identify potential obstructions, stones, or abscesses. Cystoscopy is another optional diagnostic procedure in certain cases.

Treatment and Management of Acute Cystitis

Antibiotic therapy is the mainstay of acute cystitis treatment. First-line antibiotics for uncomplicated cystitis include nitrofurantoin, trimethoprim-sulfamethoxazole (SMX-TMP), and fosfomycin. Nitrofurantoin is often preferred due to low resistance rates and effectiveness, but it’s not suitable for pyelonephritis or patients with impaired renal function. SMX-TMP is effective when local resistance is low. Fosfomycin offers a single-dose option and activity against resistant organisms.

Complicated cystitis typically requires longer antibiotic courses (10 to 14 days). Antimicrobial selection should be individualized, considering patient factors, local resistance patterns, allergies, and renal function. Second-line agents include beta-lactams, doxycycline, or fluoroquinolones. In cases of severe symptoms or suspected systemic involvement, initial parenteral antibiotics may be used.

Other management strategies include increased fluid intake and symptomatic relief with urinary analgesics like phenazopyridine for dysuria. For recurrent UTIs, prophylactic measures such as methenamine, D-mannose, and behavioral modifications may be considered.

Acute Cystitis Differential Diagnosis

It is essential to consider other conditions that can mimic the symptoms of acute cystitis. The differential diagnosis of acute cystitis includes:

  1. Vaginitis: In women, vaginitis is a common cause of dysuria. Key differentiating features include vaginal discharge, itching, odor, and dyspareunia (painful intercourse). Vaginitis can be caused by bacterial vaginosis, yeast infections (candidiasis), or trichomoniasis. Unlike cystitis, vaginitis typically does not present with urinary urgency or frequency as primary symptoms.

  2. Urethritis: Urethritis, inflammation of the urethra, can also cause dysuria and urinary frequency. In sexually active women, sexually transmitted infections (STIs) like Chlamydia trachomatis and Neisseria gonorrhoeae are common causes. Urinalysis in urethritis may show pyuria but typically lacks significant bacteriuria. A thorough sexual history and STI testing are crucial in differentiating urethritis from cystitis.

  3. Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC): PBS/IC is a chronic condition characterized by bladder pain, urinary frequency, and urgency without evidence of infection. It is a diagnosis of exclusion, made after ruling out infections and other urological conditions. Patients with PBS/IC typically have long-term symptoms without positive urine cultures.

  4. Prostatitis: In men, prostatitis (inflammation of the prostate gland) can present with symptoms similar to cystitis, such as dysuria, frequency, and urgency. However, prostatitis may also include perineal, pelvic, or ejaculatory pain, and systemic symptoms like fever and malaise. Prostatitis is often associated with a tender prostate on rectal exam.

  5. Pelvic Inflammatory Disease (PID): PID, an infection of the female reproductive organs, can sometimes cause lower abdominal pain and urinary symptoms. However, PID typically presents with pelvic pain, fever, and cervical discharge, which are less common in uncomplicated cystitis.

  6. Atrophic Vaginitis: In post-menopausal women, atrophic vaginitis due to estrogen deficiency can cause dysuria, vaginal dryness, and discharge. This condition is distinguished by vaginal dryness, pale vaginal tissues, and the absence of urinary urgency and frequency characteristic of cystitis.

  7. Urinary Tract Stones: While often causing flank pain and hematuria, small urinary stones passing through the urethra can cause dysuria and frequency, mimicking cystitis. However, pain associated with stones is typically colicky and may radiate to the groin.

  8. Bladder Cancer in Situ: Although rare, bladder cancer in situ can present with irritative voiding symptoms, including dysuria and frequency, mimicking cystitis. This is more likely in older patients with risk factors for bladder cancer and persistent symptoms despite antibiotic treatment.

  9. Radiation Cystitis: Patients who have received pelvic radiation therapy can develop radiation cystitis, characterized by dysuria, hematuria, and frequency. History of radiation therapy is a key differentiating factor.

  10. Chemical or Irritant Cystitis: Exposure to certain chemicals or irritants, such as feminine hygiene products or bubble baths, can cause bladder irritation and symptoms resembling cystitis. History of exposure and lack of infection on urinalysis are important clues.

[alt text: Table summarizing the differential diagnosis of acute cystitis, listing conditions and distinguishing symptoms.]
| Differential Diagnosis | Distinguishing Symptoms |
| :——————————- | :———————————————————— |
| Vaginitis | Vaginal discharge, itching, odor, dyspareunia, no urinary urgency or frequency as primary symptoms |
| Urethritis | Pyuria without bacteriuria, sexual history, STI risk factors |
| Painful Bladder Syndrome (PBS/IC) | Chronic symptoms, bladder pain, negative urine cultures |
| Prostatitis | Perineal/pelvic/ejaculatory pain, fever, tender prostate in men |
| Pelvic Inflammatory Disease (PID) | Pelvic pain, fever, cervical discharge |
| Atrophic Vaginitis | Post-menopausal, vaginal dryness, pale vaginal tissues |
| Urinary Tract Stones | Colicky pain, hematuria, pain radiating to groin |
| Bladder Cancer in Situ | Persistent irritative symptoms, risk factors for bladder cancer |
| Radiation Cystitis | History of pelvic radiation therapy |
| Chemical/Irritant Cystitis | Exposure history, no infection on urinalysis |

Prognosis of Acute Cystitis

Uncomplicated acute cystitis generally has a good prognosis. Symptoms typically improve within three days of starting antibiotic treatment. However, recurrent cystitis is common, affecting about 25% of women within six months of an initial UTI. Complications from uncomplicated cystitis are rare, especially with prompt and appropriate treatment.

Emphysematous cystitis, a rare but serious complication, involves gas formation in the bladder wall and is more common in diabetics. It presents with more severe abdominal pain and may require catheter drainage and, in severe cases, surgical intervention.

Complications of Cystitis

Potential complications of cystitis, though uncommon, include:

  • Pyelonephritis (kidney infection)
  • Renal or perinephric abscess
  • Renal vein thrombosis
  • Sepsis
  • Acute renal failure
  • Emphysematous pyelonephritis
  • Prostatitis (in men)

Deterrence and Patient Education

Patient education is crucial for preventing recurrent cystitis. Key recommendations include:

  • Adherence to prescribed antibiotic regimens.
  • Increased oral fluid intake.
  • Post-intercourse voiding for sexually active individuals.
  • Prompt follow-up if symptoms worsen or do not improve.
  • Maintaining good personal hygiene practices, including proper wiping techniques and avoiding irritants.

Pearls and Other Considerations

  • Consider bladder instillation therapy for patients undergoing dialysis or intermittent self-catheterization to manage recurrent UTIs.
  • Methenamine with vitamin C or D-mannose may be considered for UTI prophylaxis, especially in recurrent cases, although further research is ongoing.
  • Newer antibiotics like gepotidacin are under development and may offer alternatives for treating resistant UTIs in the future.
  • Vaccine development for UTI prevention is ongoing, showing promise for future preventative strategies.

Enhancing Healthcare Team Outcomes

Effective management of cystitis, especially in complex cases or recurrent infections, benefits from an interprofessional healthcare team approach. This includes primary care clinicians, pharmacists, nurses, and urologists. Patient education on fluid intake, medication compliance, and hygiene practices is essential. Referral to a urologist is recommended for patients with recurrent infections or complicated cases to ensure comprehensive evaluation and management.

Conclusion

Accurate differential diagnosis of acute cystitis is crucial for effective patient care. While bacterial infection is the primary cause of acute cystitis, various other conditions can mimic its symptoms. A thorough understanding of these differential diagnoses, combined with appropriate diagnostic evaluation and targeted treatment, ensures optimal outcomes and reduces the risk of complications. Healthcare professionals should consider the broad spectrum of conditions that can present with dysuria and urinary frequency to provide accurate and timely care for patients presenting with symptoms suggestive of acute cystitis.

References

  1. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13507.
  2. Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D. COSUTI: a protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults. Trials. 2019 Feb 07;20(1):106.
  3. Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur). 2010 Apr;5(2):111-5.
  4. Byron JK. Urinary Tract Infection. Vet Clin North Am Small Anim Pract. 2019 Mar;49(2):211-221.
  5. Karamali M, Shafabakhsh R, Ghanbari Z, Eftekhar T, Asemi Z. Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression. J Cell Physiol. 2019 Aug;234(8):12301-12308.
  6. Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infect Dis. 2018 Nov;5(11):ofy297.
  7. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ., EMERGEncy ID Net Study Group. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerg Infect Dis. 2016 Sep;22(9):1594-603.
  8. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR., VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013 Nov;57(9):1256-65.
  9. Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278.
  10. Suárez Fernández ML, Ridao Cano N, Álvarez Santamarta L, Gago Fraile M, Blake O, Díaz Corte C. A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients. Diagnostics (Basel). 2021 Aug 12;11(8)
  11. Sabih A, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Complicated Urinary Tract Infections.
  12. Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol. 1993 May;149(5):1046-8.
  13. Tyagi P, Moon CH, Janicki J, Kaufman J, Chancellor M, Yoshimura N, Chermansky C. Recent advances in imaging and understanding interstitial cystitis. F1000Res. 2018;7
  14. Pinto H, Simões M, Borges A. Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2021 Jul 08;10(7)
  15. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013 Nov 14;369(20):1883-91.
  16. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002 May 22-29;287(20):2701-10.
  17. Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009 Jun;57(6):963-70.
  18. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019 Aug;202(2):282-289.
  19. Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc. 2014 Feb;15(2):133-9.
  20. Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract. 2011 May 19;12:36.
  21. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ. 2019 Feb 27;364:l440.
  22. Kulchavenya EV, Neymark AI, Borisenko DV, Kapsargin FP. [Acute uncomplicated cysititis: do we follow the guidelines?]. Urologiia. 2018 Dec;(6):66-69.
  23. Phamnguyen TJ, Murphy G, Hashem F. Single centre observational study on antibiotic prescribing adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infection. Infect Dis Health. 2019 May;24(2):75-81.
  24. Bono MJ, Leslie SW, Reygaert WC, Doerr C. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections (Nursing)
  25. Bono MJ, Leslie SW, Reygaert WC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections.
  26. Swamy S, Kupelian AS, Khasriya R, Dharmasena D, Toteva H, Dehpour T, Collins L, Rohn JL, Malone-Lee J. Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis. Int Urogynecol J. 2019 Mar;30(3):409-414.
  27. May M, Schostak M, Lebentrau S., MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2019 Feb;30(2):335-336.
  28. Bellazreg F, Abid M, Lasfar NB, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study. Pan Afr Med J. 2019;33:131.
  29. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004 Apr 15;38(8):1150-8.
  30. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians. Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-827.
  31. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc. 2011 Jun;86(6):480-8.
  32. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64.
  33. Sheele JM, Libertin CR, Fink I, Jensen T, Dasalla N, Lyon TD. Alkaline Urine in the Emergency Department Predicts Nitrofurantoin Resistance. J Emerg Med. 2022 Mar;62(3):368-377.
  34. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999 Mar;43 Suppl A:67-75.
  35. Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, Poulakou G, Hatzipapas A, Koratzanis G. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother. 2003 Mar;47(3):897-900.
  36. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999 Oct;29(4):745-58.
  37. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis. 1988 Jun;157(6):1239-42.
  38. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999 Nov;21(11):1864-72.
  39. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321-47.
  40. Schulz GS, Schütz F, Spielmann FVJ, da Ros LU, de Almeida JS, Ramos JGL. Single-dose antibiotic therapy for urinary infections during pregnancy: A systematic review and meta-analysis of randomized clinical trials. Int J Gynaecol Obstet. 2022 Oct;159(1):56-64.
  41. Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020 Jul 01;75(7):1993-1997.
  42. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. Open Forum Infect Dis. 2022 Jan;9(1):ofab620.
  43. Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8.
  44. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, Bru JP, Mckinnon C, O’Doherty B, Spiegel W, Van Balen FA, Menday P. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis. 2002;34(7):487-92.
  45. Nace DA, Perera SK, Hanlon JT, Saracco S, Anderson G, Schweon SJ, Klein-Fedyshin M, Wessel CB, Mulligan M, Drinka PJ, Crnich CJ. The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents. J Am Med Dir Assoc. 2018 Sep;19(9):765-769.e3.
  46. Cox L, He C, Bevins J, Clemens JQ, Stoffel JT, Cameron AP. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J. 2017 Sep;11(9):E350-E354.
  47. Lala V, Leslie SW, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Acute Cystitis.
  48. Ziadeh T, Chebel R, Labaki C, Saliba G, Helou EE. Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review. Urologia. 2022 May;89(2):261-267.
  49. Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014 May;12(5):549-54.
  50. Kevorkian CG, Merritt JL, Ilstrup DM. Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder. Mayo Clin Proc. 1984 Aug;59(8):523-9.
  51. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84.
  52. Kyriakides R, Jones P, Somani BK. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2021 Sep;7(5):1166-1169.
  53. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Aug;223(2):265.e1-265.e13.
  54. De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics (Basel). 2021 Apr 01;10(4)
  55. Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007 Jan;86(1):47-53.
  56. Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007 Jul;100(1):17-20.
  57. Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infect Dis Ther. 2022 Dec;11(6):2297-2310.
  58. Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322.
  59. Tiffany C, Dumont EF, Hossain M, Srinivasan M, Swift B. Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects. Clin Transl Sci. 2022 Sep;15(9):2251-2264.
  60. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother. 2016 Jan 04;60(3):1918-23.
  61. Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol. 1997 Jun;157(6):2049-52.
  62. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003 Sep;170(3):867-9.
  63. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007 Apr;177(4):1349-53; quiz 1591.
  64. Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D’Antonio E, Krejci KG, Shore N, Peterson J, Lukes AS, Starks CM. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Hum Vaccin Immunother. 2021 May 04;17(5):1262-1270.
  65. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997 Apr 25;276(5312):607-11.
  66. Forsyth VS, Himpsl SD, Smith SN, Sarkissian CA, Mike LA, Stocki JA, Sintsova A, Alteri CJ, Mobley HLT. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection. mBio. 2020 Apr 28;11(2)
  67. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013 Dec;190(6):1981-9.
  68. Wang Q, Sun M, Ma C, Lv H, Wang Q, Liu G, Hu Z, Gao Y. Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review. Medicine (Baltimore). 2018 Nov;97(45):e11272.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *